Toward Therapeutic Drug Monitoring of Lenalidomide in Hematological Malignancy? Results of an Observational Study of the Exposure-Safety Relationship

Toward Therapeutic Drug Monitoring of Lenalidomide in Hematological Malignancy? Results of an Observational Study of the Exposure-Safety Relationship

Objective: Continuous lenalidomide (LEN) therapy is important to achieve a therapeutic effect in patients with multiple myeloma (MM) and non-Hodgkin lymphoma (NHL). However, despite dose adjustment according to kidney function, many patients discontinue LEN therapy because of hematological toxicity....

Full description

Bibliographic Details
Main Authors: Zaiwei Song, Lan Ma, Li Bao, Yi Ma, Ping Yang, Dan Jiang, Aijun Liu, Lu Zhang, Yan Li, Yinchu Cheng, Fei Dong, Rongsheng Zhao, Hongmei Jing
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Pharmacology
Subjects:
lenalidomide
hematological toxicity
therapeutic drug monitoring
trough concentration
hematological malignancies
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.931495/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.931495/full

Similar Items